secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2026-05-13T00:09:52+00:00
Accession:  0001701478-26-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial
-----------------------------------------------------------

- Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.
- Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.
- Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.
- Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.
- Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/0001701478-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztr-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001701478-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer